Pfizer Inc.
CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
Last updated:
Abstract:
The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
Status:
Application
Type:
Utility
Filling date:
31 Jan 2019
Issue date:
1 Aug 2019